Assessing Cumulative, Meaningful Benefits of Disease-Modifying Therapies Targeting Synucleinopathies: Conference Proceedings and Roadmap for Research
This document summarizes a 2024 workshop on disease-modifying therapies (DMTs) for synucleinopathies (Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy). Workshop attendees discussed factors that will affect access to DMTs.